NSE filing, NSE: RELIGARE. Summary written from the filing by ALFA Finder's alert engine.
Religare Enterprises Ltd: key numbers
- Share price
- ₹214.50
- Market cap
- ₹7,395 Cr
- Revenue (annual)
- ₹8,459 Cr
- Net profit (annual)
- ₹85.96 Cr
- P/E (TTM)
- 318.8×Sector 19.7×
- Promoter holding
- 31.26%+0.70% QoQ
- FII holding
- 9.76%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Religare Enterprises Ltd
All →Religare Enterprises Other Announcement
Religare Enterprises has filed its quarterly shareholding pattern for the period ending September 30, 2026, as per SEBI Regulation 31(1)(b).
Religare Enterprises Management Change
Religare disclosed Mr. Gaurav Sharma as CTO of subsidiary Religare Finvest, effective October 6, 2026. He brings ~30 years of fintech experience from IIFL and L&T Financial.
Religare Enterprises Annual General Meeting
Religare Enterprises Limited held its 42nd Annual General Meeting on September 24, 2026, where members adopted financial statements and approved the re-designation of Mr. Arjun Lamba.
Religare Enterprises Debt & Borrowing: ₹100 Cr
Religare Enterprises' subsidiary, Care Health Insurance Limited, has allotted non-convertible debentures aggregating to ₹100 Crore. These securities will be listed on the NSE.
- Value
- ₹100.0 Cr
Religare Enterprises Other Announcement
Religare Enterprises Limited has approved the continuation of Mr. Rajender Mohan Malla as the Non-Executive Chairperson for the quarter ending December 31, 2026.
Religare Enterprises Legal & Regulatory
Religare Enterprises informed that the Securities Appellate Tribunal dismissed its appeal against an earlier SEBI order. The company is sharing this legal update for record.
Other employee stock options announcements
All →Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.
Maxvolt Energy Industries Employee Stock Options
Maxvolt Energy granted 5,01,726 ESOPs to six employees under its MEIL ESOP 2025 scheme at exercise prices of ₹30 and ₹45. Options vest over four years, with exercise windows following vesting.
- Execution
- Vesting over 4 years from grant (25% at 2nd, 25% at 3rd, 50% at 4th anniversary); exercise over 3 years from each vesting date